Castle Biosciences Stock Alpha and Beta Analysis
| CSTL Stock | USD 29.51 0.30 1.01% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Castle Biosciences. It also helps investors analyze the systematic and unsystematic risks associated with investing in Castle Biosciences over a specified time horizon. Remember, high Castle Biosciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Castle Biosciences' market risk premium analysis include:
Beta 1.19 | Alpha (0.10) | Risk 3.24 | Sharpe Ratio 0.0304 | Expected Return 0.0985 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Castle |
Castle Biosciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Castle Biosciences market risk premium is the additional return an investor will receive from holding Castle Biosciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Castle Biosciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Castle Biosciences' performance over market.| α | -0.1 | β | 1.19 |
Castle Biosciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Castle Biosciences' Buy-and-hold return. Our buy-and-hold chart shows how Castle Biosciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Castle Biosciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Castle Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Castle Biosciences shares will generate the highest return on investment. By understating and applying Castle Biosciences stock market price indicators, traders can identify Castle Biosciences position entry and exit signals to maximize returns.
Castle Biosciences Return and Market Media
The median price of Castle Biosciences for the period between Wed, Aug 28, 2024 and Tue, Nov 26, 2024 is 30.36 with a coefficient of variation of 6.39. The daily time series for the period is distributed with a sample standard deviation of 1.96, arithmetic mean of 30.65, and mean deviation of 1.69. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 1250 shares by Oelschlager Kristen M of Castle Biosciences at 29.969 subject to Rule 16b-3 | 09/03/2024 |
2 | Disposition of tradable shares by Derek Maetzold of Castle Biosciences at 30.024 subject to Rule 16b-3 | 09/04/2024 |
3 | Disposition of 150 shares by Derek Maetzold of Castle Biosciences at 29.457 subject to Rule 16b-3 | 09/09/2024 |
4 | New Data at ASTRO 2024 Shows Castle Biosciences DecisionDx-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatm... | 09/27/2024 |
5 | Disposition of 150 shares by Derek Maetzold of Castle Biosciences at 28.734 subject to Rule 16b-3 | 10/04/2024 |
6 | Castle Biosciences CEO Derek Maetzold sells stock for 165,463 | 10/16/2024 |
7 | Acquisition by Olson Tiffany of 830 shares of Castle Biosciences subject to Rule 16b-3 | 10/21/2024 |
8 | Castle Biosciences, Inc. Q3 2024 Earnings Call Transcript | 11/05/2024 |
9 | Disposition of 934 shares by Derek Maetzold of Castle Biosciences at 32.528 subject to Rule 16b-3 | 11/06/2024 |
10 | Castle Biosciences Upgraded to Strong Buy Heres Why | 11/07/2024 |
11 | Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx-Melanoma and MyPath Melanoma at the American Society of Dermatopathol... | 11/08/2024 |
12 | Disposition of 299 shares by Derek Maetzold of Castle Biosciences at 34.15 subject to Rule 16b-3 | 11/12/2024 |
13 | Novavax Q3 Earnings Sales Beat, Stock Falls 6 percent on 24 View Cut | 11/13/2024 |
14 | RNA Stock Hits Record High on Entering the Cardiac Disease Space | 11/14/2024 |
15 | Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year | 11/19/2024 |
16 | Castle Biosciences Inc Stock Price Down 3.36 percent on Nov 20 | 11/20/2024 |
17 | Are Medical Stocks Lagging AnaptysBio This Year | 11/25/2024 |
About Castle Biosciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Castle or other stocks. Alpha measures the amount that position in Castle Biosciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 6.21 | 6.77 | 4.38 | 3.88 | Days Of Inventory On Hand | 46.62 | 45.38 | 64.44 | 44.02 |
Castle Biosciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Castle Biosciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Castle Biosciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Castle Biosciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Castle Biosciences. Please utilize our Beneish M Score to check the likelihood of Castle Biosciences' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Castle Biosciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Castle Biosciences Backtesting, Castle Biosciences Valuation, Castle Biosciences Correlation, Castle Biosciences Hype Analysis, Castle Biosciences Volatility, Castle Biosciences History and analyze Castle Biosciences Performance. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Castle Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.